Trial abstract · §3
MARITIDE-PH3 — results
Primary endpoint, absolute and relative effect where derivable, and harms as reported.
§3Results
§3.1Primary endpoint
Table 3. Primary endpoint as reported.
| Endpoint | Result as reported | Certainty |
|---|---|---|
| Percentage change in body weight from baseline | no result held by the Institute | Not rated |
| The Institute publishes no effect estimate for a trial whose report it does not hold. | ||
§3.2Harms as reported
Table 5. Adverse events for Maridebart cafraglutide from the safety tables the Institute holds for this compound. Where a row names a different trial as its source, the figure is from that trial and not from this one.
| Event | Active, % | Comparator, % | Source trial |
|---|---|---|---|
| Nausea | — | — | High incidence on first dose, attributed to the loading regimen; substantially lower on subsequent doses |
| Vomiting | — | — | Reported at high incidence on initiation |
| Injection-site reaction | — | — | Reported |
| Discontinuation for adverse events | — | — | Concentrated in the first dosing interval |
Compound Evidence Institute · CEI-TR-0149/3 · https://compoundevidence.com/trials/maritide-ph3/results/ · retrieved 30 July 2026